Compare Stocks: AMPH, INDV, OGN, and TARS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$25.37 -0.2%	$22.56	$16.65 ▼ $29.52	$1.08B	0.9	520,719 shs	454,519 shs
INDV Indivior	$35.99 +0.8%	$36.71	$22.56 ▼ $42.81	$4.25B	0.87	2.17 million shs	3.00 million shs
OGN Organon & Co.	$13.72 0.0%	$13.69	$5.69 ▼ $13.78	$3.60B	1.55	5.30 million shs	2.88 million shs
TARS Tarsus Pharmaceuticals	$74.46 +2.0%	$73.07	$53.89 ▼ $91.53	$3.27B	0.44	755,095 shs	939,604 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	0.00%	-2.68%	+9.71%	+29.68%	-4.93%
INDV Indivior	0.00%	-0.31%	+2.20%	-10.70%	+54.12%
OGN Organon & Co.	0.00%	+0.01%	-0.31%	+1.57%	+24.60%
TARS Tarsus Pharmaceuticals	0.00%	-3.55%	-19.59%	+8.87%	+12.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$25.37 -0.2%	$22.56	$16.65 ▼ $29.52	$1.08B	0.9	520,719 shs	454,519 shs
INDV Indivior	$35.99 +0.8%	$36.71	$22.56 ▼ $42.81	$4.25B	0.87	2.17 million shs	3.00 million shs
OGN Organon & Co.	$13.72 0.0%	$13.69	$5.69 ▼ $13.78	$3.60B	1.55	5.30 million shs	2.88 million shs
TARS Tarsus Pharmaceuticals	$74.46 +2.0%	$73.07	$53.89 ▼ $91.53	$3.27B	0.44	755,095 shs	939,604 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	0.00%	-2.68%	+9.71%	+29.68%	-4.93%
INDV Indivior	0.00%	-0.31%	+2.20%	-10.70%	+54.12%
OGN Organon & Co.	0.00%	+0.01%	-0.31%	+1.57%	+24.60%
TARS Tarsus Pharmaceuticals	0.00%	-3.55%	-19.59%	+8.87%	+12.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	1.75	Reduce	$22.50	-11.83% Downside
INDV Indivior	2.71	Moderate Buy	$45.17	25.51% Upside
OGN Organon & Co.	1.71	Reduce	$11.40	-16.88% Downside
TARS Tarsus Pharmaceuticals	2.80	Moderate Buy	$100.86	35.42% Upside

Current Analyst Ratings Breakdown

Latest AMPH, INDV, OGN, and TARS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
9/24/2026	TARS Tarsus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$116.00
9/24/2026	TARS Tarsus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$116.00
9/16/2026	TARS Tarsus Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$110.00
9/16/2026	TARS Tarsus Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$110.00
9/8/2026	TARS Tarsus Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$88.00 ➝ $105.00
9/4/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
9/4/2026	TARS Tarsus Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$88.00 ➝ $105.00
8/21/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/18/2026	AMPH Amphastar Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$20.00 ➝ $23.00
8/12/2026	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$97.00 ➝ $100.00

(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$719.89M	1.51	$4.27 per share	5.98	$17.17 per share	1.49
INDV Indivior	$1.24B	3.43	$2.74 per share	13.13	($0.78) per share	-46.14
OGN Organon & Co.	$6.22B	0.58	$5.79 per share	2.37	$2.89 per share	4.75
TARS Tarsus Pharmaceuticals	$451.36M	7.24	N/A	N/A	$8.09 per share	9.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$98.09M	$1.69	15.10	9.85	4.90	10.76%	14.98%	6.96%	11/5/2026 (Estimated)
INDV Indivior	$210M	$2.79	12.90	9.40	N/A	26.65%	-283.11%	36.85%	10/29/2026 (Estimated)
OGN Organon & Co.	$187M	$0.77	17.81	3.99	1.27	3.41%	88.97%	6.03%	11/9/2026 (Estimated)
TARS Tarsus Pharmaceuticals	-$66.42M	-$1.09	N/A	124.13	N/A	-7.67%	-13.53%	-8.12%	11/3/2026 (Estimated)

Latest AMPH, INDV, OGN, and TARS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q3 2026	INDV Indivior	$1.06	N/A	N/A	N/A	$329.35 million	N/A
8/6/2026	Q2 2026	AMPH Amphastar Pharmaceuticals	$0.62	$0.91	+$0.29	$0.67	$179.92 million	$183.90 million
8/6/2026	Q2 2026	TARS Tarsus Pharmaceuticals	-$0.1918	-$0.43	-$0.2382	-$0.43	$169.65 million	$173.91 million
8/3/2026	Q2 2026 & Merger	INDV Indivior	$0.8690	$1.15	+$0.2810	$4.90	$306.23 million	$343.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.58%	N/A	10.39%	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest AMPH, INDV, OGN, and TARS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/17/2026	INDV Indivior	special	$8.13		10/30/2026	10/30/2026	11/6/2026
7/31/2026	OGN Organon & Co.	quarterly	$0.02	0.58%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.79	2.40	1.71
INDV Indivior	N/A	0.84	0.66
OGN Organon & Co.	8.43	1.95	1.44
TARS Tarsus Pharmaceuticals	0.21	3.20	3.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
INDV Indivior	60.33%
OGN Organon & Co.	77.43%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	29.60%
INDV Indivior	0.74%
OGN Organon & Co.	1.62%
TARS Tarsus Pharmaceuticals	9.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,976	42.54 million	29.95 million	Optionable
INDV Indivior	838	118.03 million	117.16 million	Not Optionable
OGN Organon & Co.	10,000	262.61 million	258.36 million	Not Optionable
TARS Tarsus Pharmaceuticals	370	43.88 million	39.65 million	Optionable

AMPH, INDV, OGN, and TARS Headlines

Recent News About These Companies

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

October 5 at 2:28 AM | americanbankingnews.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Now Rated "Moderate Buy" by Wall Street Analysts

October 5 at 2:28 AM | marketbeat.com

Head-To-Head Survey: Tarsus Pharmaceuticals (NASDAQ:TARS) & Astrazeneca (NYSE:AZN)

October 4 at 3:58 AM | americanbankingnews.com

Tarsus to Present 11 Abstracts at Anaheim Eye Meeting

September 29, 2026 | ocbj.comO

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry ...

September 29, 2026 | markets.businessinsider.com

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting

September 29, 2026 | globenewswire.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to "Strong-Buy" at The Goldman Sachs Group

September 26, 2026 | marketbeat.com

Tarsus Pharmaceuticals (TARS) Receives a Buy from Goldman Sachs

September 25, 2026 | theglobeandmail.com

Reviewing Aurora Cannabis (NASDAQ:ACB) and Tarsus Pharmaceuticals (NASDAQ:TARS)

September 24, 2026 | americanbankingnews.com

Bank of America Corp DE Acquires New Stake in Tarsus Pharmaceuticals, Inc. $TARS

September 20, 2026 | marketbeat.com

Tarsus Pharmaceuticals Insider Sold Shares Worth $979,744, According to a Recent SEC Filing

September 19, 2026 | finance.yahoo.com

Pyott David E I Executes Options in Tarsus Pharmaceuticals, Retains 9,575 Shares

September 18, 2026 | kalkinemedia.comK

Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded by Barclays to Strong-Buy Rating

September 18, 2026 | marketbeat.com

William Phd Link Sells 12,500 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

September 17, 2026 | marketbeat.com

Hsbc Holdings PLC Grows Stake in Tarsus Pharmaceuticals, Inc. $TARS

September 12, 2026 | marketbeat.com

Wellington Management Group LLP Purchases 24,117 Shares of Tarsus Pharmaceuticals, Inc. $TARS

September 11, 2026 | marketbeat.com

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $905,600.00 in Stock

September 10, 2026 | insidertrades.com

Squarepoint Ops LLC Buys 54,791 Shares of Tarsus Pharmaceuticals, Inc. $TARS

September 10, 2026 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Moderate Buy" from Analysts

September 10, 2026 | marketbeat.com

Bobak Azamian Sells 10,000 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

September 9, 2026 | marketbeat.com

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $942,637.50 in Stock

September 9, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH, INDV, OGN, and TARS Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$25.37 -0.06 (-0.24%)

Closing price 04:00 PM Eastern

Extended Trading

$25.37 0.00 (0.00%)

As of 05:34 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Indivior NASDAQ:INDV

$35.99 +0.28 (+0.78%)

Closing price 04:00 PM Eastern

Extended Trading

$36.29 +0.30 (+0.84%)

As of 07:07 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Organon & Co. NYSE:OGN

$13.72 -0.01 (-0.04%)

Closing price 03:59 PM Eastern

Extended Trading

$13.72 0.00 (0.00%)

As of 04:43 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Tarsus Pharmaceuticals NASDAQ:TARS

$74.46 +1.46 (+2.00%)

Closing price 04:00 PM Eastern

Extended Trading

$74.38 -0.08 (-0.11%)

As of 05:37 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMPH, INDV, OGN, and TARS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMPH, INDV, OGN, and TARS Earnings

Compare Dividends

Latest AMPH, INDV, OGN, and TARS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMPH, INDV, OGN, and TARS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH, INDV, OGN, and TARS Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

Indivior NASDAQ:INDV

Organon & Co. NYSE:OGN

Tarsus Pharmaceuticals NASDAQ:TARS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMPH, INDV, OGN, and TARS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMPH, INDV, OGN, and TARS Earnings

Compare Dividends

Latest AMPH, INDV, OGN, and TARS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMPH, INDV, OGN, and TARS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH, INDV, OGN, and TARS Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

Indivior NASDAQ:INDV

Organon & Co. NYSE:OGN

Tarsus Pharmaceuticals NASDAQ:TARS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools